Familial forms account for about 10% of ALS cases, although higher levels have been reported in certain geographical regions. The lifetime risk for developing the disease is approximately 1/400. ALS has a very poor prognosis, with a median survival period of three years after the onset of the initial symptoms. There is no cure for this relentless disease, although the drug riluzole, which blocks the release of glutamate, has been shown to slow disease progression.
Genetic background
The genetics of ALS are of research interest because it helps to uncover the mechanism of cell death in ALS. Neuronal cytoplasmic protein aggregation and defective RNA metabolism show to be frequent pathogenic mechanisms involved in ALS. Regarding its genetic background, more than 20 major ALS genes have been implicated in the Mendelian ALS forms and further about 100 genes have been associated as predisposing factors with the non-Mendelian variants. ALS can be inherited in an autosomal dominant, autosomal recessive or X-linked manner. 
Angiogenin (ANG)
The ANG gene encodes angiogenin, a 123-residue, 14.1-kDa protein and it is located on chromosome 14q11.2. The ANG protein belongs to pancreatic ribonuclease superfamily, and it plays a role in rRNA biogenesis, cellular proliferation and has a crucial role in inhibiting protein translation by cleaving tRNA. 
Senataxin (SETX)
Mutations in the senataxin (SETX) gene have been identified at a lower frequency than in the SOD1 gene in ALS. SETX encodes a helicase protein involved in DNA repair and RNA production.
Fused in sarcoma (FUS)
The fused in sarcoma (FUS) gene is also associated with the Mendelian forms of ALS. FUS is located on chromosome 16p11.2 and encodes for a 526 amino acid protein. FUS is a nucleoprotein that plays a role in transcription, splicing, and shuttling of RNA from the nucleus to the cytoplasm. Fused in sarcoma also acts as a transcriptional regulatory sensor of DNA damage signals and therefore is required in maintaining the integrity of the genome.
Aims
In my thesis, the primary aim was to summarize the results of my genetic investigations in a group of Hungarian patients (n=66) suffering from ALS. I investigated the contributions of six commonly mutated ALS genes, SOD1, TARDBP, ANG, FUS, SETX and C9orf72.
This study represents the first genetic screening of ALS in Hungary, which adds novel data to the genetic and phenotypic diversity of this disease. 
PATIENTS AND METHODS

Patients
The unrelated patients (n=66) included in this study were recruited from the Department of Neurology, University of Szeged, Szeged, Hungary, between 2010 and 2016. All patients fulfilled the revised El Escorial and the Awaji-shima criteria for ALS. The investigation was approved by the Internal Ethical Review Board of the University of Szeged. Written informed consent was obtained from patients and healthy controls, and the study was conducted according to the Principles of the Declaration of Helsinki.
Methods
DNA isolation
Blood samples from all the enrolled individuals (n=66) were collected after the individuals had signed an informed consent document. Genomic DNA was isolated using a QIAamp DNA Blood Mini Kit (QIAGEN; Hilden, Germany).
Mutation Screening -Sanger Sequencing
The entire coding region and the flanking introns of the SOD1, TARDBP and ANG genes were amplified. Direct sequencing of the PCR products was performed on an ABI 3100 sequencer and compared with the wild-type gene sequences. Fragments with identified mutations were independently re-amplified and resequenced from both ends.
Repeat expansion analysis
Repeat-primed PCR and Fragment length analysis
A two-step protocol was followed for the detection of the GGGGCC hexanucleotide RE in the C9orf72 gene. The presence of the GGGGCC RE was observed as a sawtooth pattern with 6-base pair periodicity.
Genotyping
To determine whether the single individual carrying the GGGGCC RE identified in this study also carried the "risk" haplotype, I selected the rs3849942 variant to be used as a marker for the "risk" haplotype for the patient and control genotypes.
Rs3849942 genotyping was based on allelic discrimination assays using TaqMan chemistry following the manufacturer's instructions. 
Targeted
Bioinformatic analysis
To improve the efficiency of the Roche pipeline, composed of the Roche 454 GS Reference Mapper for mapping (on UCSC human reference genome hg19) and Amplicon Variant Analyzer (v2.5p1) for variant calling, an additional in house pipeline was used.
RESULTS
SOD1 gene
The direct DNA sequencing approach identified four different mutations of the SOD1 gene in 5 ALS patients: three known heterozygous missense mutations (c.43G>A p.Val14Met; c.272A>C p.Asp90Ala; c.435G>C p.Leu144Phe) and one novel mutation (c.275_276delAA, p.Lys91ArgfsTer8).
Novel mutation detected in the SOD1 gene
The detected novel heterozygous mutation (c.275_276delAA, p.Lys91ArgfsTer8) is located in the fourth exon of the SOD1 gene and led to a frameshift with the insertion of 8 novel amino acids and the formation of premature stop codon at the new amino acid position 99. The novel p.Lys91ArgfsTer8 SOD1 mutation was not present in 110 healthy controls of Hungarian ancestry that I investigated neither it is represented in mutation databases. 
Detected known mutations of the SOD1 gene
The SOD1 p.Leu144Phe mutation is located in the fifth exon of the gene and was identified in two female ALS patients.
The p.Val14Met mutation is located in the first exon of the SOD1 gene and was present in an affected female patient who reported no family history of ALS. ALS symptoms first appeared at the age of 62.
The p.Asp90Ala mutation, which is the most prevalent SOD1 mutation in Europe, is located in the fourth exon of the SOD1 gene and was present in a female patient.
Interestingly, the patient also carried the rs111273304 splice-donor variant (c.239+2T>A), which is of unknown significance, in heterozygous form. This patient had clinical features typically associated with this genotype, including a relatively long survival after onset.
TARDBP gene
Direct sequencing of the TARDBP gene revealed a previously described missense mutation in exon 6 (c.931A>G, p.Met311Val). The variant was first described by 
C9orf72 gene
Analysis of the C9orf72 gene identified GGGGCC RE in one out of 66 ALS patients.
The average repeat number based on fragment-length analysis was 5 (range 2-17 repeats) in the remaining 65 patients, none of whom carried repeat expansion. The patient with the repeat expansion also carried the rs3849942 risk allele, which was previously described as a part of the Finnish "risk" haplotype.
SETX gene
A novel heterozygous missense mutation (c.791A>G, p.Asn264Ser) of the SETX gene was identified in a Hungarian female patient. The novel c.791A>G, p.Asn264Ser SETX mutation identified in this study was confirmed with direct sequencing. The mutation was absent in the patient's clinically healthy 45-year-old son and in the age-and gender-matched healthy control individuals. The heterozygous p.Asn264Ser mutation affects the N-terminal region of the SETX protein and is located in a region which is conserved among mammals.
DISCUSSION
In this study, I analyzed SOD1, TARDBP, ANG, C9orf72, SETX and FUS genes in a cohort of 66 Hungarian ALS patients, including one single case with a reported familial history for the disease.
Mutations in the SOD1 gene
I identified a novel and likely disease-causing heterozygous frameshift mutation (p.Lys91ArgfsTer8) in the SOD1 gene. Three other heterozygous recurrent SOD1 missense mutations (p.Val14Met, p.Asp90Ala and p.Leu144Phe) were also detected.
SOD1 mutations were detected in 7.5%
The two-base-pair deletion of the p.Lys91ArgfsTer8 SOD1 mutation leads to a frameshift with the formation of a premature stop codon after the insertion of eight novel amino acids, causing a severe truncation of the protein. This truncation abolishes the integrity of the intrachain C57-C146 disulfide bridge.
The p.Asp90Ala mutation is the most common SOD1 mutation in Europe, and it can be inherited in either a dominant or recessive manner.
The p.Leu144Phe missense mutation, which is the most prevalent mutation in the Balkan region (ALSoD), was detected in a familial and in a sporadic case. The rare p.Val14Met mutation was detected in an apparently sporadic case in a female patient 12 with upper and lower motor neuron signs. None of the SOD1 mutations detected in these ALS patients was identified in 110 healthy Hungarian controls. 
Mutations in the TARDBP
Repeat expansion of the C9orf72 gene
C9orf72 repeat expansion was detected only in one patient of 66. The patient carrying the RE variant also carried the previously described rs3849942 risk allele in heterozygous form. The presence of the risk allele suggests that the common founder is also shared by the Hungarian patient with the RE. These results suggest that the frequency of RE observed in the Hungarian ALS patients (1,5%) is significantly lower than in Western European populations, further demonstrating that the frequency of genetic factors for ALS varies among different geographic regions. The identified novel p.Asn264Ser SETX mutation is associated with an unusual ALS phenotype characterized by lower motor neuron impairment only.
This study further widens the geographic range for the origin of disease-causing heterozygous missense mutations of the SETX gene, which have already been implicated in ALS in patients from different countries. To my knowledge, my study is the first demonstrating a novel SETX mutation in the Hungarian ALS population.
Mutations in the FUS gene
No mutations in FUS, were detected in the Hungarian patients. The patients (n=66) participating in this study were recruited from the Department of Neurology, University of Szeged. Genomic DNA was isolated from blood. SOD1, TARDBP and ANG genes were analysed by Sanger sequencing. The GGGGCC hexanucleotide repeat in C9orf72 was analyzed by a two-step protocol, including a first step of polymerase chain reaction amplification using genotyping primers. The fragment length analysis was performed using GeneScan. Only samples presenting with a single peak/amplification product were further analyzed in the second step by repeat-primed polymerase chain reaction. Targeted high-throughput sequencing was used for the analysis of the coding regions of the SETX, FUS and C9orf72 genes.
Direct sequencing revealed a novel heterozygous frameshift mutation (c.275_276delAA, p.Lys92ArgfsX8) and three recurrent missense mutations (p.Val14Met; p.Asp90Ala and p.Leu144Phe in two patients) in the SOD1 gene in five patients. The novel heterozygous SOD1 mutation (p.Lys91ArgfsTer8) is located in the fourth exon of the gene and led to a frameshift with the insertion of 8 novel amino acids and the formation of premature stop codon at the new amino acid position 99. A known missense mutation (p.Met311Val) was detected in the TARDBP gene, which is located in the C-terminal part of the protein, the glycine-rich
